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SUMMARY
Infant mortality from dengue disease is a devastating global health burden that could be minimized with the
ability to identify susceptibility for severe disease prior to infection. Although most primary infant dengue in-
fections are asymptomatic, maternally derived anti-dengue immunoglobulin G (IgGs) present during infection
can trigger progression to severe disease through antibody-dependent enhancement mechanisms. Impor-
tantly, specific characteristics ofmaternal IgGs that herald progression to severe infant dengue are unknown.
Here, we defineR10% afucosylation of maternal anti-dengue IgGs as a risk factor for susceptibility of infants
to symptomatic dengue infections. Mechanistic experiments show that afucosylation of anti-dengue IgGs
promotes FcgRIIIa signaling during infection, in turn enhancing dengue virus replication in FcgRIIIa+ mono-
cytes. These studies identify a post-translational modification of anti-dengue IgGs that correlateswith risk for
symptomatic infant dengue infections and define a mechanism by which afucosylated antibodies and
FcgRIIIa enhance dengue infections.
INTRODUCTION
Antibody-mediated inflammatory responses are critical in immu-
nity against infectious organisms. These responses can promote
pathogen clearance but can also exacerbate symptoms during
infections (Bournazos et al., 2017). Antibody-mediated inflam-
mation is triggered when pathogens or infected cells are bound
by immunoglobulin G (IgG) antibodies, forming immune com-
plexes that signal through Fc gamma receptors (FcgRs) on
effector cells. The outcome of effector cell responses depends
on the balance of activating to inhibitory (A/I) FcgR signaling
that arises from interactions with Fc domains within immune
complexes. Activating FcgRs contain immunoreceptor tyro-
sine-based activation motifs (ITAMs), while the inhibitory FcgR
balances this activity through immunoreceptor tyrosine-based
inhibitorymotif (ITIM) signaling. One factor thatmodulates the ra-
tio of A/I FcgR signaling is the glycosylation state of the IgG Fc
domains within immune complexes. For example, sialylation of
the Fc promotes anti-inflammatory effector responses, whereas
absence of core fucosylation, afucosylation, of the Fc is pro-in-
flammatory due to increasing affinity of the Fc for the activating
FcgRIIIa, found on natural killer (NK) cells, as well as on subsets
of macrophages and monocytes (Anthony et al., 2011; Bourna-
zos et al., 2017; Rafiq et al., 2013). The second major determi-
nant of A/I FcgR signaling by immune complexes is the distribu-
tion of IgG subclasses within the complex, with IgG1 being the
dominant subclass promoting pro-inflammatory responses and
IgG2 signaling through the inhibitory FcgR (Pincetic et al., 2014).
Dengue virus infections are unusual in that non-neutralizing
anti-dengue virus IgGs can play a central role in triggering pro-
gression to the severe forms of disease through antibody-
dependent enhancement (ADE) mechanisms (Anderson et al.,
2014; Burke et al., 1988; Chau et al., 2009; Guzma´n et al.,
1990; Halstead et al., 1970; Katzelnick et al., 2017; Libraty
et al., 2009; Sangkawibha et al., 1984; Wang et al., 2017). ADE
can occur in the presence of reactive, non-neutralizing IgGs,
as are found in secondary heterologous dengue infections or in
primary infections in infants of dengue-immune mothers due to
acquisition of anti-dengue virus IgGs during gestation (Halstead
et al., 1970; Kliks et al., 1988; Simmons et al., 2007). These
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antibodies are thought to promote disease by forming immune
complexes with the virus that modulate infection in FcgR-
bearing cells, primarily monocytes and macrophages, leading
to higher viral titers and altered cytokine production during infec-
tion (Aye et al., 2014; Durbin et al., 2008; Kou et al., 2008; Thein
et al., 1997). Still, the vast majority of dengue infections that
occur in the presence of non-neutralizing IgGs are asymptom-
atic, and specific features of antibodies that enhance one’s basal
susceptibility for dengue disease are unknown. Importantly,
mortality rates in severe dengue can exceed 20% when patients
are not hospitalized, but can be reduced to <1% with in-patient
care (Anderson et al., 2014; Gordon et al., 2013). Therefore, the
identification of serologic markers for increased baseline sus-
ceptibility to dengue disease could dramatically reducemortality
associated with these viruses by enabling early hospitalization of
those at highest risk for disease progression.
Because maternal IgGs are transferred to the fetus during
gestation, we hypothesized that the repertoire of maternal anti-
dengue virus IgG Fc domains might impact basal susceptibility
of infants to disease during dengue virus infections. To address
this, we performed a global analysis of maternal anti-dengue IgG
Fc domain features from a prospective cohort of mothers and in-
fants in a dengue-endemic region of the Philippines in order to
define characteristics that predicted progression to significant
infant dengue disease. We found that maternal anti-dengue
IgGs enriched for afucosylated Fc glycoforms predicted clini-
cally significant disease in their infants during primary dengue in-
fections. Because afucosylation enhances affinity of the Fc for
FcgRIIIa, this suggested a role for this receptor in the pathogen-
esis of dengue disease. We therefore performed studies to
dissect the mechanism by which FcgRIIIa and afucosylated
IgGs impact dengue virus infections. Our findings identify a
pathway by which dengue replication can be enhanced through
a FcgRIIIa signaling mechanism requiring the calcineurin
signaling network. These studies identify a mechanistic basis
for differential susceptibility to dengue disease based on the
presence of afucosylated anti-dengue IgGs and suggest novel
strategies for the treatment of dengue virus infections.
RESULTS
Maternal Anti-Dengue Fucosylation Predicts
Susceptibility to Clinically Significant Disease during
Infant Dengue Infections
Maternal IgG levels in the serum of newborns generally match or
exceed those inmaternal serum (1,012mg/mL IgG), and the half-
life of maternal IgGs in infants is >40 days (Watanaveeradej et al.,
2003). Thus, when a mother is seropositive for dengue viruses,
maternal anti-dengue IgGs have the potential to modulate infant
dengue infections for over 1 year after birth (Alkan Ozdemir et al.,
2016; Nicoara et al., 1999; Simmons et al., 2007; Thompson
et al., 2016).
To define specific maternal anti-dengue IgG features that her-
ald risk for infant dengue disease, we performed a global anal-
ysis of anti-dengue envelope (E) IgGs in mothers of infants with
symptomatic (febrile) or asymptomatic primary dengue infec-
tions. To do this, we studied samples from a prospective cohort
in San Pablo, Laguna, Philippines, a dengue-endemic region.
After delivery, infants were followed rigorously for primary
dengue infections, including documentation of subclinical infec-
tions evidenced by seroconversion (Capeding et al., 2010; Li-
braty et al., 2009).
Given the role of FcgRs in ADE of dengue virus infections, we
first askedwhether anymaternal anti-E Fc glycosylation patterns
could predict susceptibility to infant dengue disease. Character-
ization of anti-E IgG Fc glycoforms showed that mothers of in-
fants who had clinically significant (symptomatic) primary
dengue infections had significantly increased levels of afucosy-
lated anti-E Fc glycoforms compared with mothers of infants
who had asymptomatic primary infections (Figure 1A). Indeed,
R10% afucosylated Fc glycans was predictive of elevated risk
for symptomatic infant dengue infections; this threshold pre-
dicted symptomatic infections in infants with a positive predic-
tive value of 88%. Specificity of this marker was 93%, indicating
that it nearly always predicted symptomatic dengue infections in
infants. Sensitivity was lower, 46%, as many, but not all, symp-
tomatic infections could be predicted using this serologic
marker. Even omitting the sample with the highest level of afuco-
sylation in the symptomatic group, the 10% threshold remained
predictive with unchanged specificity (93%) and slightly reduced
sensitivity (43%). Interestingly, this specific threshold of afucosy-
lation was also identified in a prior study of hospitalized dengue
patients; this prior study found that anti-E IgGwithR10%afuco-
sylated Fc glycans was predictive of the most severe disease
outcomes during acute dengue infections that occurred in the
presence of reactive, non-neutralizing IgGs (Wang et al., 2017).
Aside from Fc fucosylation, other Fc glycoforms did not vary be-
tween mothers of infants with symptomatic and asymptomatic
primary dengue infections (Figure 1B).
Besides Fc glycosylation, the other features that can impact
the A/I ratio of Fc-FcgR interactions were also measured. Exten-
sive characterization of the maternal anti-E IgG response
showed that symptomatic infant dengue infections could not
be predicted by the IgG1/IgG2 ratio of anti-E subclasses, a mea-
surement that accounts for the most abundant IgG subclasses,
with IgG1 having increased affinity for activating FcgRs over
IgG2 (Figure 1C). The distribution of all maternal anti-E IgG sub-
classes, the titer of anti-E IgGs, and the binding avidity of anti-E
IgGs (Figures 1D–1F) were also not different between groups. In
addition, there was no correlation between either symptomatic
infant dengue infections or the levels of maternal anti-E afucosy-
lation with infant sex, age at infection, days of fever during symp-
tomatic infections, or serotype of the infecting dengue virus
strain (Table S1). Because anti-NS1 IgGs can modulate the
severity of dengue infections, we further assessed whether the
maternal titer of anti-NS1 IgGs predicted symptomatic dengue
infections in their infants and found no correlation (Figure S1A)
(Hertz et al., 2017; Jayathilaka et al., 2018). In addition, there
was no significant difference in the abundance of anti-NS1 or to-
tal IgG Fc fucosylation frommothers of infants with symptomatic
or asymptomatic primary dengue infections (Figure S1B). The
presence of R10% afucosylated glycans on anti-E IgG was
the only factor identified in our characterizations that predicted
risk for dengue disease in infants. Because Fc afucosylation in-
creases affinity for FcgRIIIa, this finding pointed toward a role
for FcgRIIIa in antibody-enhanced dengue infections.
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FcgRIIIa Signaling Is Driven by the Fucosylation Level in
Dengue Immune Complexes and Enhances Dengue
Virus Replication in Human U937 Monocytes
To study how FcgRIIIa signaling by dengue immune complexes
might be impacted by variable levels of anti-E fucosylation, we
used the maternal IgGs to generate dengue immune complexes
and defined their signaling capacity in a FcgRIIIa reporter assay.
This showed a linear correlation between endogenously pro-
duced levels of anti-E afucosylation and FcgRIIIa-mediated
signaling (Figure 2A). Next, we generated dengue virus immune
complexes using pooled maternal IgGs with R10% or <10%
afucosylation of anti-E IgG; immune complexes withR10% afu-
cosylation drove significantly higher FcgRIIIa signaling (Fig-
ure 2B). To assess whether anti-E domain specificity might
modulate FcgRIIIa signaling activity, we expressed monoclonal
antibodies (mAbs) that bound to distinct domains of the E protein
with fucosylated or afucosylated Fc glycans. All mAbs triggered
significantly enhanced FcgRIIIa signaling when expressed with
afucosylated Fc glycoforms regardless of their anti-E binding
specificity (Figure 2C; Figure S2; Table S2).
Although FcgRIIIa is present on macrophage and pro-inflam-
matory monocyte subsets that are associated with dengue dis-
ease, FcgRIIIa is not expressed on human monocytic or other
granulocytic lineage cell lines that are often used to study ADE
of dengue virus infections, such as THP-1, K562, or U937 cells
(Fleit et al., 1982; Tridandapani et al., 2002; van de Winkel and
Anderson, 1991). These cell lines express the high-affinity acti-
vating FcgR, FcgRI (except for K562 cells), along with the low-af-
finity FcgRs, activating FcgRIIa and inhibitory FcgRIIb. Further,
primary cells and in vivo mouse models are not robust systems
for studying the role of FcgRIIIa in dengue infections because
FcgRIIIa is unstable on primary monocytes/macrophages that
are cultured ex vivo (Ong et al., 2019; Wang lab, unpublished
data), and mouse models that are humanized for FcgR expres-
sion, and thus express FcgRIIIa, are immunocompetent,
rendering them incompatible with current dengue infection
models (Smith et al., 2012; Zellweger and Shresta, 2014).
Thus, to dissect the role of FcgRIIIa in ADE of dengue infections,
we generated human U937 monocytes expressing different
combinations of the activating low-affinity FcgRs, FcgRIIa and
A B C
D E F
Figure 1. Maternal Anti-E IgG Characterization
Anti-E Fc glycoforms were characterized.
(A) Fucosylation of Fc glycoforms was significantly different in abundance between mothers of infants with symptomatic (red) and asymptomatic (black) dengue
infections, with afucosylated Fc glycans significantly increased in mothers of infants with symptomatic dengue infections.R10% afucosylated Fc glycans was
predictive of elevated risk for symptomatic infant dengue infections with a positive predictive value of 88%.
(B) No significant differences in other Fc glycoforms, bisected (N), galactosylated (G), or sialylated (S), were observed.
(C–F) There were also no differences in the maternal anti-E (C) IgG1/IgG2 subclass ratio, (D) IgG subclass distribution, (E) IgG titer on dengue-infected cells, or (F)
IgG avidity between mothers of infants who developed symptomatic or asymptomatic primary dengue infections.
Each symbol (A–F) represents an individual donor. Data are representative of one experiment per donor (A–D) or three experiments (E and F); (A–C and F)
horizontal bars represent mean of clinical samples. Significance was assessed by unpaired Student’s t test, where p < 0.05 was considered significant; *p < 0.05.
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FcgRIIIa (Figures S3A–S3F). FcgRIIa was previously shown to
have a role in ADE of dengue infections (Boonnak et al., 2013),
but a role for FcgRIIIa has not been defined.
First, U937 monocytes expressing different combinations of
FcgRIIa and FcgRIIIa were infected with immune complexes
made from dengue virus and five different maternal IgGs from
the San Pablo cohort. Single-cycle infection was enhanced by
up to 300% in monocytes expressing FcgRIIIa (FcgRIIa+Fc-
gRIIIa+) compared with those expressing only FcgRIIa
(FcgRIIa+FcgRIIIa) (Figure 3A). Next, we determined whether
FcgRIIIa ITAM signaling was required for FcgRIIIa-mediated
ADE, using cells expressing signaling-competent (FcgRIIa+Fc-
gRIIIa+) or signaling-null [FcgRIIa+FcgRIIIa(ITAM)] versions of
FcgRIIIa (Figure S3A) (Bla´zquez-Moreno et al., 2017). Interest-
ingly, the FcgRIIIa-mediated enhancement of infection required
ITAM signaling (Figure 3A). To assess whether anti-E domain
specificity might contribute to the involvement of FcgRIIIa in
ADE, we tested the panel of afucosylated anti-E mAbs for their
ability to modulate dengue infections. In all cases, anti-E mAbs
mediated significantly increased infection in FcgRIIa+FcgRIIIa+
cells over U937 monocytes expressing only FcgRIIa. As
observed with the maternal IgG, FcgRIIIa-mediated ADE
required FcgRIIIa signaling in all cases (Figure 3B). Overall, these
studies showed that increasing the cellular A/I FcgR signaling ra-
tio via FcgRIIIa ITAM signaling promoted ADE of dengue virus
infections.
We next asked whether modulating cellular A/I FcgR signaling
in parallel with dengue infection might impact ADE. Crosslinking
individual FcgRs in FcgRIIa+FcgRIIIa+ U937 cells showed that
increased signaling by the activating, ITAM-containing FcgRIIa
or FcgRIIIa enhanced cell infectibility, whereas signaling through
the inhibitory, ITIM-containing FcgRIIb reduced infection (Fig-
ure 3C). These results are consistent with increased A/I signaling
ratios promoting ADE of dengue infections, whereas reducing
the A/I ratio via FcgRIIb signaling diminished ADE. Additive acti-
vating/ITAM signaling through crosslinking FcgRIIa and FcgRIIIa
together resulted in the greatest enhancement of infection (Fig-
ure 3D). These data supported a mechanism whereby infection
A B
C
Figure 2. Anti-E Fucosylation in Dengue Virus Immune Complexes Determines FcgRIIIa Signaling by Effector Cells
Dengue immune complexes were generated from maternal serum IgGs.
(A) FcgRIIIa signaling was linearly correlated with the abundance of afucosylated Fc glycoforms of anti-DENV E IgGs within immune complexes, n = 29.
(B) Dengue immune complexes generated from pooled maternal IgGs with R10% anti-E afucosylation triggered significantly more FcgRIIIa signaling when
compared with immune complexes generated from pooled maternal IgGs with <10% anti-E afucosylation. Both pools were generated from sera of mothers of
infants who experienced symptomatic primary dengue infections.
(C) Fucosylation of distinct anti-E mAbs modulates FcgRIIIa signaling. Fucosylated (black circles) or afucosylated (white circles) anti-DENV E mAbs with distinct
Fab specificities were tested for the ability to trigger FcgRIIIa signaling. Enhanced FcgRIIIa signaling by afucosylated immune complexes was observed in all
cases. GRLR is a non-FcgR-binding Fc variant.
Each point in (A) represents an individual donor. Data shown in (B) and (C) are representative of three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
(unpaired Student’s t test). Data in (A)–(C) are representative of a minimum of three experiments. Error bars (B and C) represent the standard error of three
technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the width of the symbol
marking the data point.
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Figure 3. FcgRIIIa Signaling Enhances Antibody-Dependent Infection of U937 Monocytes
(A) Infection by dengue immune complexes generatedwithmaternal IgGswas significantly enhanced in FcgRIIIa+monocytes, and FcgRIIIa signalingwas required for
enhancement in all cases. Red line: FcgRIIa+FcgRIIIa+ cells; black line: FcgRIIa+FcgRIIIa cells; broken red line, unfilled circles: FcgRIIa+FcgRIIIa(ITAM) cells.
(B) The role of FcgRIIIa signaling in ADE was evaluated by comparison of infection in FcgRIIa+FcgRIIIa+ cells (red), FcgRIIIa-signaling null FcgRIIa+FcgRIIIa(ITAM)
cells (white), and FcgRIIa+FcgRIIIa (black) or FcgRIIaFcgRIIIa (blue) cells. Immune complexes were generated from dengue virus and afucosylated anti-
envelope mAbs 235, B7, 2D22, or C10, which have distinct anti-E binding specificities. In all cases, FcgRIIIa signaling was required for maximal infection.
(C) Signaling induced by crosslinking of FcgRIIa or FcgRIIIa promoted infection of FcgRIIa+FcgRIIIa+ U937 cells, whereas crosslinking the inhibitory FcgR,
FcgRIIb, reduced infectibility of cells.
(D) Combined signaling by activating FcgRIIa and FcgRIIIa during infection resulted in maximal infectibility of FcgRIIa+FcgRIIIa+ U937 cells.
(E) Increasing cellular calcium flux promoted infection of FcgRIIa+FcgRIIIa+ U937 cells.
*p < 0.05, **p < 0.01, ***p < 0.001, ***p < 0.0001 (unpaired Student’s t test). Data are representative of a minimum of three experiments. Error bars represent the
standard error of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than the
width of the symbol marking the data point.
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was enhanced by cellular calcium flux, which is triggered by
ITAM signaling (Bolland and Ravetch, 1999; Hippen et al.,
1997). To verify this, we treated cells with the calcium ionophore,
ionomycin, prior to infection. This treatment increased ADE of
infection in a dose-dependent manner (Figure 3E).
Having found that FcgRIIIa ITAM signaling could increase
dengue infections, we next sought to determine whether
FcgRIIIa might have a separate role in mediating attachment of
dengue immune complexes. To investigate this, we used well-
characterized blockingmAbs against FcgRI, FcgRIIa, or FcgRIIIa
to prevent immune complex attachment to cells prior to infection
(Boruchov et al., 2005; Fleit et al., 1982; Mandelboim et al., 1999;
Tamm and Schmidt, 1996; Zeller and Sullivan, 1993). In FcgRIIa+
FcgRIIIa+ U937 cells, blocking either FcgRI or FcgRIIa during im-
mune complex attachment prevented 50% infection, whereas
blocking FcgRIIIa alone with the blocking mAb, 3G8, did not
inhibit infection (Figure 4A) (Boruchov et al., 2005; Fleit et al.,
1982; Mandelboim et al., 1999; Tamm and Schmidt, 1996; Zeller
and Sullivan, 1993). Combining blocking mAbs for FcgRI and
FcgRIIa inhibited infection by 80%, and inclusion of the
FcgRIIIa blocking mAb did not further diminish infection. In
freshly isolated primary monocytes, blocking attachment of im-
mune complexes to FcgRIIa prior to entry prevented nearly all
infection, whereas blocking FcgRI, FcgRIIb, or FcgRIIIa did not
reduce infection (Figure 4B). These results are consistent with
studies showing that FcgRIIa on monocytes mediates dengue
immune complex attachment and entry (Boonnak et al., 2013;
Kou et al., 2008; Littaua et al., 1990) and suggested that the
FcgRIIIa-mediated enhancement is due to modulation of a
post-attachment step of infection.
Inhibitors of the Calcineurin Signaling Network Block
Dengue Virus Replication
Engagement and crosslinking of the activating FcgRs trigger
phosphorylation of ITAM domains by Src family kinases and
intracellular calcium flux (Bournazos and Ravetch, 2015; Hippen
et al., 1997). Calcium flux, in turn, activates calcineurin, a serine/
threonine phosphatase that recognizes a host of substrates,
scaffolds, and regulator proteins through specific dockingmotifs
(Roy andCyert, 2009; Roy et al., 2007). To dissect how enhanced
A/I ratios contribute to ADE of dengue infections, we treated cells
with inhibitors of the ITAM signaling pathway prior to infection.
First, FcgRIIa+FcgRIIIa+ monocytes were treated with PRT, an
inhibitor of Syk tyrosine kinase activity, required for initiation of
ITAM signaling (Lowell, 2011; Reilly et al., 2011). This inhibited
dengue infection (Figure 5A), supporting the requirement for
ITAM signaling in ADE of dengue virus infection.
Next, we tested the hypothesis that ADE of dengue infection is
enhanced by calcium flux via the calcineurin signaling network.
The small-molecule inhibitor INCA-6 (Bretz et al., 2013) and the
peptide inhibitor 11R-VIVIT (VIVIT) (Aramburu et al., 1999) act
selectively to prevent the association of calcineurin with sub-
strates that bind via the calcineurin PxIxIT docking motif (Roy
et al., 2007). Both inhibitors prevented dengue virus infection in
U937 monocytes (Figures 5B and 5C). Inhibitors were used at
concentrations that did not impact cell viability (Figure S4). To
assess the specificity of this observation for dengue infections,
we studied the impact of the VIVIT inhibitor on infection of
U937 cells by influenza A viruses. Although dengue serotypes
2 and 3 were robustly inhibited by VIVIT, influenza A viruses
(H1N1 A/Netherlands/602/2019 and H3N2 A/HK/1/1968 strains)
were not affected by this inhibitor of the calcineurin signaling
network (Figure 5D). We next treated cells with the VIVIT inhibitor
during or at different time points after dengue infection to char-
acterize the kinetics of the required calcineurin network activity.
Treatment of cells up to 6 h after entry significantly reduced
infection, consistent with disruption of a post-entry stage of
infection (Figure 5E). Interestingly, FK506 and cyclosporin A,
two clinically used drugs that block calcineurin through mecha-
nisms distinct from INCA-6 and VIVIT (Ho et al., 1996), did not
prevent dengue infections (Figure S5). These studies show that
calcineurin-PxIxIT site interactions are required for maximal
dengue virus infections, suggesting new clinical strategies for
treatment of dengue infections.
IgG Fucosylation Is Stable over Time, Suggesting Utility
as a Predictive Marker for Dengue Disease Risk
To be a useful marker of dengue disease susceptibility, the abun-
dance of Fc afucosylation would have to be stable over time and
withstand immune perturbation. To assess stability of this IgG
modification, we performed a longitudinal study of IgGs from
healthy adults in a North American cohort who were challenged
with influenza A virus (Memoli et al., 2015). We characterized IgG
afucosylation prior to and over a period of 60 days after influenza
Figure 4. FcgRIIIa Does Not Mediate Virus
Immune Complex Attachment during ADE in
Monocytes
(A) Individual or combined FcgRs were blocked
during the viral attachment step of infection in
FcgRIIa+ FcgRIIIa+ U937 monocytes. Blocking
FcgRIIa and/or FcgRI during immune complex
attachment significantly reduced infection, whereas
blocking FcgRIIIa did not impact infection.
(B) Blocking FcgRIIa alone during attachment in
primary monocytes prevented their infection,
whereas blocking FcgRI, FcgRIIb, or FcgRIIIa did
not impact infection.
**p < 0.01, ***p < 0.001, ****p < 0.0001 (unpaired
Student’s t test). Data are representative of a mini-
mum of three experiments. Error bars represent the
standard error of three technical replicates.
6 Cell Reports 31, 107642, May 12, 2020
Article
ll
OPEN ACCESS
A B C D
E F
G
Figure 5. Inhibition of Dengue Infection through Targeted Inhibition of ITAM Signaling Pathway Elements
(A) A small molecule that targets Syk tyrosine kinase (Syk TK), PRT, inhibited dengue infection in FcgRIIa+FcgRIIIa+ U937 monocytes.
(B and C) A small-molecule inhibitor, INCA-6 (B), and a peptide inhibitor, 11R-VIVIT (VIVIT) (C), which act by blocking calcineurin-substrate interactions at the
calcineurin PxIxIT site, inhibited dengue infections. A scrambled peptide containing the amino acids found in VIVIT (11R VEET) did not inhibit infection (open
circles).
(D) Inhibition of dengue viruses (DENV2, DENV3), but not H1N1 or H3N2 influenza viruses (IAVs), was observed using the VIVIT inhibitor (solid lines); scrambled
VEET peptide in dashed lines.
(E) Treatment of cells with VIVIT up to 6 h after infection by dengue immune complexes significantly inhibited infection.
(F) Model for susceptibility to clinically significant dengue infections in infants. Infants of mothers who are dengue-immune and haveR10% afucosylated anti-E
IgGs are at elevated risk for symptomatic primary dengue infections due to modulation of FcgRIIIa-expressing cells during infection.
(G) Model for the roles of FcgRIIa, FcgRIIIa, and afucosylated dengue immune complexes in ADE.While FcgRIIa supports amajority of viral attachment and entry,
FcgRIIIa signaling increases cellular ITAM signaling. ITAM signaling, in turn, triggers calcium flux andmodulates the calcineurin signaling network, which supports
dengue virus replication.
*p < 0.05, **p < 0.01, ****p < 0.0001 (unpaired Student’s t test). Data are representative of a minimum of three experiments. Error bars represent the standard error
of three technical replicates. Replicates were performed at all points; where error bars are not present, the standard error was smaller than thewidth of the symbol
marking the data point.
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virus challenge. The abundance of afucosylated glycans was
remarkably durable over this period and, despite virus challenge
(Figure S6), supporting utility of this serologic marker to guide
clinical care of dengue patients.
DISCUSSION
Here, we show that elevated afucosylated Fc glycans (R10%)
on maternal anti-E IgGs is one risk factor for susceptibility of in-
fants to disease during primary dengue virus infections. Mecha-
nistic studies performed to identify how afucosylated anti-E IgGs
can impact dengue infections support a model whereby the
presence of afucosylated dengue immune complexes triggers
a FcgRIIIa-modulated infection characterized by increased
ITAM signaling. Enhanced ITAM signaling, in turn, promoted
dengue infections in U937 monocytes through an intrinsic ADE
mechanism (Figure 5F) (Halstead et al., 2010). On a cellular level,
the data show a role for FcgRIIIa in enhancing ADE of dengue vi-
rus infections through cooperativity with FcgRIIa. Although
FcgRIIa acts in virus immune-complex attachment and entry
(extrinsic ADE) (Halstead et al., 2010), we show that the
increased cellular A/I signaling ratio triggered by afucosylated
immune complex-FcgRIIIa interactions supports dengue virus
infection through calcineurin signaling network interactions
requiring the PxIxIT docking motif (Figure 5G). This mechanism
suggests novel treatment strategies for dengue infections that
target this pathway.
An important topic for future studies on the pathogenesis of
dengue disease is the cellular activities associated with afucosy-
lated IgGs during dengue infection that were not studied here.
We have used percent infection as the readout of activity
conferred by anti-dengue Fc afucosylation and of FcgRIIIa
signaling in ADE of dengue virus infections, yet FcgRIIIa signaling
activity likely impacts disease pathogenesis through multiple
mechanisms, including modulation of cytokine production by
FcgRIIIa-expressing cells.
Because mortality rates in severe dengue cases can be nearly
eliminated with intensive clinical monitoring (Anderson et al.,
2014; Gordon et al., 2013), identifying markers for susceptibility
to dengue disease could dramatically improve the clinical man-
agement of dengue patients. Here we show that maternal IgG
Fc fucosylation could be used in the cohort studied to identify
a significant subset of susceptible infants. Prospective cohort
studies are now needed to examine testing of antibody fucosy-
lation to guide the treatment of primary infant dengue infections
and acute dengue infections in non-infant populations.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
FITC conjugated anti-human FcgRIIa, clone IV.3 STEMCELL Technologies Cat#60012FI; RRID: AB_2722545
Brilliant Violet 711 conjugated anti-human FcgRIIIa, clone 3G8 Biolegend Cat#302044; RRID: AB_2563802
Anti-human FcgRIIb, clone 2B6 J. Ravetch, Rockefeller
University
N/A
APC anti-human FcgRI, clone 10.1 Biolegend Cat#305014; RRID: AB_1595428
Influenza A NP Monoclonal Antibody (D67J), FITC Invitrogen Cat#MA17322; RRID: AB_1017747
anti-E antibody, clone D1-4G2-4-15 ATCC Cat#VR-1852; RRID: AB_827205
Fucosylated and afucosylated human monoclonal antibody
23-5G2D2747(4)
(Sasaki et al., 2013) N/A
Fucosylated and afucosylated human monoclonal antibody B7 (Rouvinski et al., 2015) N/A
Fucosylated and afucosylated human monoclonal antibody 2D22 (de Alwis et al., 2012) N/A
Fucosylated and afucosylated human monoclonal antibody
753(3) C10
(Rouvinski et al., 2015) N/A
Fucosylated and afucosylated human monoclonal antibody 5J7 (de Alwis et al., 2012) N/A
anti- FcgRIIIa, clone 3G8 Biolegend Cat#302057; RRID: AB_2572005
anti-FcgRIIa clone IV.3 Stem Cell Technology Cat#60012; RRID: AB_2722545
Bacterial and Virus Strains
DENV2 New Guinea C BEI Resources NR-84
A/Hong Kong/1/1968, H3N2 BEI Resources NR-28620
A/Netherlands/602/2009, H1N1 Wang Lab Stock N/A
DENV3 C0360/94 BEI Resources NR-48800
Biological Samples
Sera collected at birth from 29 dengue seropositive mothers of
infants who had primary dengue infections
(Libraty et al., 2009) ClinicalTrials.gov: NCT00377754
Sera from 8 individuals challenged with Ca/04/2009/H1N1 Vero
Grown Virus. Sera were collected prior to challenge as well as on
day 30 and 60 post-challenge.
(Memoli et al., 2015) ClinicalTrials.gov: NCT01646138
Chemicals, Peptides, and Recombinant Proteins
Dengue Envelope Protein Serotype 1 Prospec DEN-021
Dengue Envelope Protein Serotype 2 Prospec DEN-022
Dengue Envelope Protein Serotype 3 Prospec DEN-023
Dengue Envelope Protein Serotype 4 Prospec DEN-024
11R-VEET Thermo Fisher Cat#CM102281.2
11R-VIVIT Thermo Fisher Cat#CM102281.1
INCA-6 Abcam Cat#ab145864
PRT062607 Fisher Scientific Cat#NC0664362
Ionomycin Invivogen Cat#inh-ion
2F-Peracetyl-Fucose EMD Millipore Cat#344827
Critical Commercial Assays
Protein G Sepharose 4 Fast Flow resin GE Healthcare Cat#17061802
NHS agarose resin ThermoFisher Cat#26196
Experimental Models: Cell Lines
FcgRIIa+FcgRIIIa+ U937 Cells This paper N/A
FcgRIIa-FcgRIIIa- U937 Cells This paper N/A
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RESOURCE AVAILABILITY
Lead Contact
The lead contact for this study is Taia T. Wang (taiawang@stanford.edu).
Materials Availability
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact.
Data and Code Availability
This study did not generate any unique datasets or code. An unpaired Student’s t test was utilized to calculate p value: *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001.
Key Resources Table
See attached file
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Clinical cohorts and samples: Samples from mothers of infants who had primary dengue infections were from a study that was
approved by the institutional review boards of the Research Institute for Tropical Medicine, Philippines, and the University of Mas-
sachusetts Medical School. Mothers and their healthy infants were recruited and enrolled after providing written informed consent
(ClinicalTrials.gov NCT00377754) (Libraty et al., 2009). Symptomatic dengue was defined as febrile illness with a positive result by
dengue serotype-specific reverse-transcription PCR in acute phase sera (Lanciotti et al., 1992). Clinically inapparent dengue infec-
tion (asymptomatic infection) was determined using a hemagglutination inhibition assay (HAI assay); aR four-fold increase in HAI
against one or more dengue serotypes in the absence of febrile illness confirmed asymptomatic infection (Libraty et al., 2009).
The outcome assessed was clinical phenotype during dengue virus infection (symptomatic infection versus asymptomatic infection)
(Table S1). Samples from the controlled influenza A virus challenge study have been previously described (Memoli et al., 2015). The
study (ClinicalTrials.gov NCT01646138) was approved by the National Institute of Allergy and Infectious Diseases institutional review
board and underwent an ethics review by the NIH Department of Bioethics prior to being conducted. The study was conducted in
accordance with the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines.
METHOD DETAILS
IgG Fc glycan and IgG subclass analysis: Methods for relative quantification of Fc Glycans and IgG subclasses have been previously
described (Wang et al., 2015; Wang et al., 2017). Briefly, IgGs were isolated from serum by protein G purification. Antigen-specific
IgGs were isolated on NHS agarose resin (ThermoFisher; 26196) coupled to the protein of interest. Mixed envelope proteins from the
four DENV serotypes were used (ProSpec; DEN-021, DEN-022, DEN-023, DEN-024). Following tryptic digestion of purified IgG
bound to antigen-coated beads, nanoLC-MS/MS analysis for characterization of glycosylation sites was performed on an Ulti-
Mate3000 nanoLC (Dionex) coupled with a hybrid triple quadrupole linear ion trap mass spectrometer, the 4000 Q Trap (SCIEX).
Continued
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MS data acquisition was performed using Analyst 1.6.1 software (SCIEX) for precursor ion scan triggered information dependent
acquisition (IDA) analysis for initial discovery-based identification.
For quantitative analysis of the glycoforms at the N297 site across the three IgG subclasses (IgG1, IgG2 and IgG3/G4), multiple-
reaction monitoring (MRM) analysis for selected target glycopeptides, was applied using the nanoLC-4000 Q Trap platform to the
samples which had been digested with trypsin. The m/z of 4-charged ions for all different glycoforms as Q1 and the fragment ion
at m/z 366.1 as Q3 for each of transition pairs were used for MRM assays. A native IgGs tryptic peptide (131-GTLVTVSSASTK-
142) with transition pair of, 575.9+2/780.4 was used as a reference peptide for normalization. IgG subclass distribution was quanti-
tatively determined by nanoLC-MRM analysis of tryptic peptides following removal of glycans from purified IgGs with PNGase F.
Here the m/z value of fragment ions for monitoring transition pairs was always larger than that of their precursor ions to enhance
the selectivity for unmodified targeted peptides and the reference peptide. All raw MRM data were processed using MultiQuant
2.1.1 (SCIEX). All MRMpeak areas were automatically integrated and inspectedmanually. In the case where the automatic peak inte-
gration by MultiQuant failed, manual integration was performed using the MultiQuant software.
U937 cell lines: Wild-type U937 cells are FcgRIIa+FcgRIIIa-; FcgRIIa was deleted from the wild-type line using CRISPR/Cas9
methods to generate FcgRIIa-FcgRIIIa- monocytes. Wild-type cells were stably transfected for expression of FcgRIIIa generating
the FcgRIIa+FcgRIIIa+. A final cell line, FcgRIIa+FcgRIIIa(ITAM/), expresses FcgRIIa and a variant of FcgRIIIa that does not associate
with the Fc receptor gamma chain, and thus lacks ITAM signaling (Bla´zquez-Moreno et al., 2017).
The gRNAs to target FcgRIIa were designed utilizing DESKGEN software, and inserted into sequence containing U6 promoter and
gRNA scaffold (Yang et al., 2014). The gRNA sequence to target human FcgRIIa was 50GATGTATGTCCCAGAAACCTG30. The final
fragment (Integrated DNA Technologies) was cloned into the pCR-BluntII-Topo vector. Human codon optimized cas9 DNA was ob-
tained from (Addgene, Plasmid #41815). To generate the knockout cell line, U937 cells were transfected with 1.5mg hCas9 and 0.5mg
of gRNA via electroporation. The U937 cells were electroporated using Lonza Nucleofector 2b (program W-001) and the Nucleofec-
tion Kit C (Lonza, VPA-1004). After electroporation, U937 cells were incubated at 37C for 48 hours. Following incubation, cells were
synchronized at the early S phase using a double thymidine block. The cells were stained with IV.3-FITC, and FcgRIIa negative cells
were bulk sorted on SH800 sorter. After one bulk sort, the cells were single cell sorted based on negative FcgRIIa expression. To
generate FcgRIIIa+ cells, the wild-type cells were nucleofected with pLJM1-EGFP plasmid (Addgene, Plasmid #19319) that has
EGFP replaced with FcgRIIIa or FcgRIIIa(ITAM/), while the FcgRIIa- cells were nucleofected with pLJMI- FcgRIIIa only. Stably trans-
fected clones were selected using 1ug/mL puromycin.
FcgRIIIa signaling assay: U937 cells were infected with DENV2 New Guinea C (BEI Resources; NR-84) at MOI2 and 0.2ug/ml
235WT. 48h post infection, cells were washed once with PBS. Infected U937 cells were added to anti-dengue mAbs or purified
maternal IgGs. Infected U937 cell immune complexes were washed and added to 100ul of Jurkat-Lucia NFAT CD16 (Invivogen;
jktl-nfat-cd16) cell suspension at a concentration 1x106cells/ml in IMID media and incubated at 37C for 24h. 20ul of assay super-
natant was then transferred to a 96-well white polystyrene clear flat bottom plate. 50ul Lucia detection medium QUANTI-Luc
(Invivogen; rep-qlc1) was added and luciferase activity was measures using Tecan Infinite M100 with a 0.1 s reading time.
FACS staining of U937 cell lines: U937 cell lines were stainedwith a fixable live/dead stain (ThermoFisher; L10119). To assess FcgR
expression cells were stained at 1:100 with a FITC conjugated anti-human FcgRIIa antibody, clone IV.3 (STEMCELL Technologies;
60012FI); Brilliant Violet 711 conjugated anti-human FcgRIII, clone 3G8 (Biolegend; 302044); an FcgRIIb antibody clone 2B6
(gifted by the Ravetch lab, Rockefeller University) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) and an APC conjugated
anti-human FcgRI, clone 10.1 (Biolegend, 305014) for 30 minutes at 4C.
Cross-linking of FcgRs for receptor signaling detection: U937 cell lines were treated with mouse anti-FcgRIIIa/b, clone 3G8
(Biolegend; 302057) at 10mg/ml in Optimem on ice for 30 min. Anti-mouse Fc was then added at 1.25mg per 1 million cells and incu-
bated at 37C for 3 min to crosslink mAb 3G8. Cells were then lysed in a one to one ratio of cell lysate buffer containing 100mMTRIS-
HCL/300mM NaCL/2% Triton X-100 and a protease/phosphatase inhibitor cocktail (ThemoFisher; 88668). Protein concentrations
were quantified using BCA Protein Assay Kit (ThermoFisher; 23227) and lysates were treated by boiling for 5 min with Laemmli
SDS sample buffer containing 5% b-mercaptoethanol. Cell lysates were run on Mini-PROTEAN TGX Precast Protein Gels (Bio
Rad; 456903). Blots were blocked 5% BSA in TBS buffer 20mM Tris-HCL/150mM NaCl pH 7.6 for 2 hours and were subsequently
incubated with anti-phosphotyrosine secondary antibody (Biolegend; 309302) at 1:1,000 in 5% BSA in TBS, 0.2% Tween-20 (TBST)
overnight at 4 C. Blots were washed and incubated with anti-mouse IgG Fc-HRP (Southern Biotech; 1030-05) at 1:10,000 for 1 hour
at room temperature. Blots were developed with Western Lightning ECL Pro (Perkin Elmer; NEL120001EA) according to manufac-
turer’s instructions. Themembranewas imaged using the Amersham Imager 600 (GE Life Sciences) with auto exposure under chemi-
luminescent detection settings. Post-imaging, the membrane was washed extensively with TBST before treating with RestoreTM
Western Blot Stripping Buffer (ThermoFisher; 21059) for 15 min at room temperature. To analyze protein loading, the membrane
was re-blocked with 5% BSA in TBST for 2 hour at room temperature before probing with a 1:200 dilution anti-vinculin 7F9 (Santa
Cruz Biotechnology; sc-73614) in 5% BSA/TBST for 1 hour at room temperature followed by anti-mouse IgG HRP secondary, as
above. The membrane was then treated with chemiluminescent substrate and imaged as described above.
Cross-linking of FcgRs in parallel with infection: Non-TC treated round bottom plates were coated with FcgR specific antibodies in
PBS for 1h at 37C. Coating antibodies: anti-FcgRIIa clone IV.3 (Stem Cell Technology; 60012) (at 5ug/ml individually or 2.5ug/ml
in conjunction with other antibodies), anti-FcgRIIb clone 2B6 (generously provided by J. Ravetch, Rockefeller University)
(at 5ug/ml individually or 2.5ug/ml in conjunction with other antibodies); and anti- FcgRIIIa, clone 3G8 (Biolegend; 302057)
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(at 10ug/ml individually or 5ug/ml in conjunction with other antibodies). Plates were coated at 10ug/ml in PBS of human IgG2/kappa
(Sigma Aldrich; AG504) to control for protein coat. Plates were washed twice and 50,000 FcgRIIa+FcgRIIIa+ U937 cells/well diluted in
OPTI-MEM were added to plate and incubated at 4C for 30min. Immune complexes composed of DENV2 New Guinea C (BEI Re-
sources; NR-84) and 0.2ug/ml mAb 235 were then added to plate and incubated at 37C for 2h. Cells were washed twice in PBS and
re-suspended in OPTI-MEM followed by an incubation for 22 h at 37C. Percent infection was detected by FACs.
Monoclonal antibody production: Antibodies: 23-5G2D2747(4)(Sasaki et al., 2013), B7 (B7)(Dejnirattisai et al., 2015; Rouvinski
et al., 2015; Swanstrom et al., 2016), 2D22(de Alwis et al., 2012; Fibriansah et al., 2015a; Swanstrom et al., 2016), and 753(3) C10
(C10)(Rouvinski et al., 2015; Swanstrom et al., 2016), 752-2 C8(de Alwis et al., 2012; Rouvinski et al., 2015; Swanstrom et al.,
2016), and 5J7(de Alwis et al., 2012; Fibriansah et al., 2015b; Swanstrom et al., 2016) were expressed in Expi293 cells as follows.
For afucosylated variants, Expi293 cells (ThermoFisher; A14527) were split to 2.03 106 cells/mL in a 10mL volume 24h prior to trans-
fection and treated with 100 mMof a fucosyl transferase inhibitor, 2F-Peracetyl-Fucose (Rillahan et al., 2012) (EMDMillipore, 344827).
On the day of transfection, 5 mg filter-sterilized DNA (2.5 mg each of heavy and light chain-encoding plasmids) was added to 1mL of
Expi293 medium (ThermoFisher Scientific; A1435101) in a fresh tube, and mixed. To this, 13 mL (1.3 mL/mL of total transfection vol-
ume) of FectPro transfection Reagent (Polyplus Transfection; 116-001) was added. The DNA-transfection reagent mixture was incu-
bated at room temperature for 10 minutes before adding dropwise to 10 mL of the Expi293 cells. The cells were then additionally
treated with a final concentration of 4g/L glucose and 3 mM valproic acid. The cells were then grown under shaking conditions
(125 rpm) at 37C for 3 days before receiving an additional 4g/L final concentration of glucose. The cells were harvested on day 6
post-transfection, the cell pellet discarded, and the supernatant media filtered before purification. MAbs were purified over Protein
G Sepharose 4 Fast Flow resin (GE Healthcare; 17061802). The antibodies were buffer exchanged into PBS pH 7.4 prior to use in any
cell-based assays.
Cell-based ELISA:Wells of a 96well plate were seededwith 3x104 Vero cells (ATCC; CCL-81). The next day cells were infectedwith
DENV2 New Guinea C (BEI Resources; NR-84) or DENV3 C0360/94 (BEI Resources; NR-48800) MOI 1 for 1 hour, washed, and incu-
bated for 48 h inMEM, 1%methylcellulose, 2% inactivated FBS, antibiotics, and L-glutamine. Cells were fixedwith 4% formaldehyde
for 30minutes and permeabilized in 2% inactivated FBS/0.1% saponin/PBS. For analysis of clinical samples, serially dilutedmaternal
sera were incubated for 2 hours at room temperature on cells infectedwith the virus serotype of the paired infant’s dengue virus infec-
tion. For mAb binding assays, mAbs were titrated and incubated for 2 hours at room temperature on DENV2 infected cells. Cells were
washed with PBS–0.1% Tween 20 and incubated with mouse anti-human IgG Fc-HRP (Southern Biotech; 9040-05) for 1 hour.
Following incubation, the wells were washed and TMB Liquid Substrate (Sigma; T0440) was added and stopped with 1M HCL after
approximately 5 minutes. Absorbance at 450 nm was measured; ELISA performed in triplicate.
Antibody-dependent infections: Anti-E mAbs were incubated with dengue viruses for 30 minutes at 37C to form immune com-
plexes. Afucosylated anti-E mAbs were used where indicated in the text. 5x104 U937 cells were added to the immune complexes
(MOI: 4) in RPMI containing 2% heat-inactivated FBS, antibiotics, MEM nonessential amino acid solution, 2-mercaptoethanol,
and HEPES. Cells were infected for 2 hours at 37C, washed, then resuspended in infection media and incubated for an additional
4-24 h at 37C. Infected cells were stained with a fixable violet live/dead stain (ThermoFisher; L34955) for 30min, fixed with 4% form-
aldehyde and permeabilized in 2% inactivated FBS, 5mM EDTA, 0.1% saponin in PBS. Cells were stained using an anti-E antibody,
clone 4G2 (ATCC; VR-1852) conjugated to Alexa Fluor 647 (ThermoFisher; A20186) at 1:400 for 30min. The frequency of infected cells
was determined using flow cytometry, defined as the percentage of live, single cells that were positive for mAb 4G2 staining. For
infections involving inhibitors or activators of ITAM signaling, U937s were treated with titrated inhibitors/activators: Ionomycin (Inviv-
ogen; inh-ion), PRT062607 (Fisher Scientific; NC0664362), INCA-6 (Abcam; ab145864), 11R-VIVIT (Thermo Fisher; CM102281.1), or
11R-VEET (Thermo Fisher; CM102281.2) in complete RPMI media for 1h-6h at 37C prior to, during or following infection as indicated.
Immune complexes were formed at 37C for 30min between hIgG1 mAb 235 and DV2 (MOI4) at 37C. U937 were washed 2 times
with PBS and then added to the immune complexes for a 2h infection at 37C. Cells were thenwashed 2x in PBS and re-suspended in
infection media followed by incubation for an additional 22 h at 37C.
FcgR blocking assay: Afucosylated anti-E monoclonal antibody 235 expressed as a human IgG1 (hIgG1) was incubated with
dengue virus for 30 minutes at 37C to form immune complexes and then cooled on ice for 15 min. FcgRIIa+FcgRIIIa+ U937 cells
or CD14+ PBMCs were incubated on ice for 30 minutes with different combinations of FcgR-specific blocking antibodies, described
above, each at 4ug/ml(Boruchov et al., 2005; Fleit et al., 1982; Zeller and Sullivan, 1993). Total antibody concentration between de-
terminants was controlled by addition of human IgG2/kappa where needed (Sigma Aldrich; AG504). Cells were washed with ice-cold
PBS and added to dengue immune complexes (MOI 5). Infection proceeded for 1 hour on ice. Cells were then washed and resus-
pended in infection media followed by incubation for an additional 22 h at 37C. Percent infection was determined by FACs.
Influenza infections of U937 cells: Influenza viruses A/Hong Kong/1/1968, H3N2 (BEI; NR-28620) and A/Netherlands/602/2009,
H1N1 in Opti-MEM were added to FcgRIIa+ FcgRIIIa+ U937 cells for 2h at 37C. Cells were then washed twice with PBS, resus-
pended in OPTI-MEM and incubated at 37C for an additional 22h. Percent infection was determined by FACs. Influenza-infected
cells were detected using Alexa488 influenza A NP monoclonal antibody clone D67J (Invitrogen; MA1-7322) at a 1:100 dilution.
For infections involving inhibitors of ITAM signaling, U937s were treated with titrated inhibitors: 11R-VIVIT (Thermo Fisher;
CM102281.1) or 11R-VEET (Thermo Fisher; CM102281.2) in complete RPMI media for 2h at 37C prior to infection. Treated cells
were washed 2x with PBS before being added to virus.
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Avidity ELISA: The avidity ELISA has been described before (Wang et al., 2015). Briefly, Wells of microtiter plates were coated with
DENV2 (ProSpec; DEN-022) or DENV3 (ProSpec; DEN-023) E proteins (2.5mg ml1 in PBS) for 2 hours at 37C. Plates were blocked
for 30 min with 1% BSA/1%PBS and then incubated with titrated Gentle Ag/Ab Elution Buffer, pH 6.6 (ThermoFisher; 21027) and
maternal IgG, which was normalized for optical density of binding to dengue-infected cells and matched for virus serotype of the
paired infant’s dengue virus infection. Plates were washed with PBS/0.1% Tween 20 and wells were incubated with alkaline phos-
phatase-conjugated anti-human Fc (Southern Biotech; P7998) followed by 2 hour incubation. Following incubation, the wells were
washed and p-nitrophenyl phosphate substrate solution (Sigma; P7998) was solution was added. Absorbance at 405 nm was
measured after approximately 45 min; ELISA performed in triplicate.
Western blot of mAbs: Antibodies were run under reducing and denaturing conditions by SDS-PAGE on a gradient gel with Tris-
Glycine buffer. The gel was transferred to a 0.45 mm nitrocellulose membrane (Bio-Rad) using semi-dry transfer. The membrane was
blocked in 5% BSA in TBST for 2 hours at room temperature, before probing with a 1:10,000 dilution of biotinylated Aleuria Aurantia
Lectin or AAL (Vector Labs; B-1395) in 5% BSA/TBST for 1 hour at room temperature. After 4-6 washes with TBST, the membrane
was incubated with a 1: 2500 dilution of streptavidin-HRP (Southern Biotech; 7100-05) in 5% BSA/TBST for 1 hour at room temper-
ature. After 4-6 washes with TBST the membrane was treated with chemiluminescent substrate Western Lightning ECL Pro (Perkin
Elmer; NEL120001EA) according to manufacturer’s instructions. The membrane was then imaged using the Amersham Imager 600
(GE Life Sciences) with auto exposure under chemiluminescent detection settings. Post-imaging, the membrane was washed exten-
sively with TBST before treating with RestoreTMWestern Blot Stripping Buffer (ThermoFisher; 21059) for 15min at room temperature.
To analyze protein loading, themembrane was re-blocked with 5%BSA in TBST for 2 hours at room temperature before probing with
1:5000 dilution of anti-human IgG-HRP (Southern Biotech) in 5%BSA/TBST for 1 hour at room temperature. Themembranewas then
treated with chemiluminescent substrate, and imaged as described above.
QUANTIFICATION AND STATISTICAL ANALYSIS
All in vitro experiments were performed using three different biological replicates at least three independent times. Normality of Fc
glycan distribution was confirmed by Kolmogorov-Smirnov test. Statistical analysis was performed with an unpaired t test. All the
analyses were performed using the GraphPad Prism 9 software (Graphpad Software, San Diego, California, USA).
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